HC Wainwright reaffirmed their buy rating on shares of Savara (NASDAQ:SVRA - Free Report) in a report released on Monday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the stock.
A number of other equities research analysts have also recently commented on SVRA. JMP Securities reaffirmed a market outperform rating and set a $8.00 price objective on shares of Savara in a research note on Monday, May 6th. Piper Sandler lifted their price target on shares of Savara from $7.00 to $16.00 and gave the stock an overweight rating in a research report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of Buy and a consensus target price of $8.20.
Check Out Our Latest Stock Analysis on SVRA
Savara Trading Down 1.4 %
Shares of SVRA stock traded down $0.07 on Monday, reaching $4.59. 699,664 shares of the stock were exchanged, compared to its average volume of 870,550. The company has a debt-to-equity ratio of 0.22, a current ratio of 14.90 and a quick ratio of 14.90. Savara has a one year low of $1.97 and a one year high of $5.70. The stock has a market cap of $634.29 million, a PE ratio of -12.41 and a beta of 0.73. The stock has a 50 day moving average price of $4.88 and a 200 day moving average price of $4.55.
Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. Equities research analysts forecast that Savara will post -0.38 EPS for the current fiscal year.
Institutional Trading of Savara
Institutional investors and hedge funds have recently bought and sold shares of the stock. AJOVista LLC acquired a new position in shares of Savara during the 4th quarter worth approximately $40,000. Principal Financial Group Inc. bought a new position in shares of Savara in the third quarter valued at about $48,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Savara during the 3rd quarter worth about $64,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Savara during the 4th quarter worth about $74,000. Finally, Tower Research Capital LLC TRC grew its stake in Savara by 665.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 19,507 shares of the company's stock valued at $92,000 after buying an additional 16,959 shares during the last quarter. Institutional investors own 87.93% of the company's stock.
Savara Company Profile
(
Get Free Report)
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Recommended Stories
Before you consider Savara, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list.
While Savara currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
